

# Global Cancer Antibody Drug Conjugates Market & Clinical Pipeline Insight 2022

<https://marketpublishers.com/r/G77BBCCBFB7EN.html>

Date: May 2017

Pages: 420

Price: US\$ 2,400.00 (Single User License)

ID: G77BBCCBFB7EN

## Abstracts

**Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.**

“Global Cancer Antibody Drug Conjugates Market & Clinical Pipeline Insight 2022” report gives comprehensive insight on various clinical and non-clinical parameters involved in the development of global cancer antibody drug conjugate market. In recent years antibody drug conjugates have emerged as new growth frontier for the companies involved in the research and development of drugs for the treatment of cancer. As per report findings, currently there are 243 antibody drug conjugates in clinical pipeline for the treatment of cancer. Majority of antibody drug conjugates for the treatment of cancer are in preclinical stage followed by research phase clinical trials. There are 6 cancer antibody drug conjugates commercially available in the market. Report helps to analyze the clinical pipeline of antibody drug conjugates by Company, Indication, Mode of Action, Formulation & Phase.

Antibody drug conjugates have emerged as new addition to the cancer therapeutic segment which is already overcrowded and consists of numerous competitors. Antibody drug conjugates are based on monoclonal antibodies which delivers drugs in highly targeted manner. Their superior pharmacological profiles have allowed the pharmaceutical companies to commercialize them in highly competitive cancer segment.

Monoclonal antibodies have quite strong hold in cancer market due to high therapeutic efficacy along with minimized side effects. But, it was realized that pharmacological profiles of presently available monoclonal antibodies would not be able to offer benefits in future as cancerous cells develop resistance. Moreover, other benefits like remission, quality of life, morbidity, mortality rates and other parameters are modest at their best.

Definitely, monoclonal antibodies are way superior as compared to their traditional counterparts but more improvement is required in order to offer better therapeutic effects. To overcome such issues, concept of antibody drug conjugates was developed; now this concept has been materialized due to availability of advanced technology.

For the cancer where validated predictive biomarkers are available, administration of targeted therapies such as antibody drug conjugates and others have been associated with unprecedented tumor response and clinical benefit. Efforts to design tolerable combination therapies involving antibody-drug conjugate, cancer vaccine, immune checkpoint and kinase inhibition are rational means of maximizing clinical benefit in the targeted delivery of anticancer therapies. The major advantage of using antibody drug conjugates is that it brings together the best characteristics of both antibodies and the cytotoxic potential of chemotherapy. This offers significant opportunity for the market in terms of targeted accumulation of drug in the tumor cell or tissue. Apart from this there are several other benefits of antibody drug conjugates which are driving the market and will be accelerating its share in the upcoming future.

“Global Cancer Antibody Drug Conjugates Market & Clinical Pipeline Insight 2022” report highlights:

Impetus of Antibody Drug Conjugates

Mechanism of Cancer Antibody Drug Conjugates

Global Cancer Antibody Drug Conjugate Clinical Pipeline Overview

Marketed Cancer Antibody Drug Conjugate Clinical Insight

Global Cancer Antibody Drug Conjugate Pipeline by Company, Indication ,  
Mode of Action, Formulation & Phase

## Contents

### **1. IMPETUS OF ANTIBODY DRUG CONJUGATES**

- 1.1 Prologue to Cancer Antibody Drug Conjugate
- 1.2 The ABCs of ADCs

### **2. STRUCTURAL ENTITIES OF ANTIBODY DRUG CONJUGATE**

- 2.1 Rational Design of Antibody Drug Conjugates
  - 2.1.1 Monoclonal Antibody
  - 2.1.2 Linker
  - 2.1.3 Drug Payload
- 2.2 Aspects of Conjugational Chemistry

### **3. REVOLUTIONIZING ANTIBODY DRUG CONJUGATES GENERATION**

- 3.1 First & Second Generation ADCs
- 3.2 Third Generation ADCs

### **4. MECHANISM OF CANCER ANTIBODY DRUG CONJUGATES**

- 4.1 Sequential Therapeutic Mechanism for Cancer
  - 4.1.1 Selecting an Appropriate Target
  - 4.1.2 Antigen Binding Complex
  - 4.1.3 Antibody Drug Conjugate Internalization
- 4.2 Approved Antibody Drug Conjugate

### **5. GLOBAL CANCER ANTIBODY DRUG CONJUGATES MARKET OVERVIEW**

### **6. GLOBAL CANCER ANTIBODY DRUG CONJUGATE CLINICAL PIPELINE OVERVIEW**

- 6.1 Phase
- 6.2 Indication
- 6.3 Mechanism of Action
- 6.4 Company
- 6.5 Formulation

## **7. GLOBAL CANCER ANTIBODY DRUG CONJUGATES MARKET DYNAMICS**

- 7.1 Favorable Market Parameters
- 7.2 Commercialization Challenges

## **8. GLOBAL CANCER ANTIBODY DRUG CONJUGATES MARKET FUTURE PROSPECTS**

- 8.1 Approaching Newer Approaches
- 8.2 Upcoming Future Market Prospects

## **9. GLOBAL CANCER ANTIBODY DRUG CONJUGATE PIPELINE BY COMPANY, INDICATION & PHASE**

- 9.1 Research
- 9.2 Preclinical
- 9.3 Clinical
- 9.4 Phase-I
- 9.5 Phase-I/II
- 9.6 Phase-II
- 9.7 Phase-II/III
- 9.8 Phase-III
- 9.9 Preregistration

## **10. MARKETED CANCER ANTIBODY DRUG CONJUGATE CLINICAL INSIGHT**

- 10.1 Brentuximab Vedotin (Adcetris)
- 10.2 Mifamurtide (Junovan & Mepact)
- 10.3 Gemtuzumab Ozogamicin (Mylotarg)
- 10.4 Trastuzumab Emtansine (Kadcyla)
- 10.5 Ibritumomab Tiuxetan (Zevalin & Zevamab)
- 10.6 Satumomab (OncoScint CR/OV)

## **11. COMPETITIVE LANDSCAPE**

- 11.1 AbbVie
- 11.2 AbGenomics Corporation
- 11.3 Biogen Idec
- 11.4 Biotest

- 11.5 Bristol-Myers Squibb
- 11.6 Celldex Therapeutics Inc
- 11.7 Helix BioPharma
- 11.8 IBC Pharmaceuticals
- 11.9 ImmunoGen
- 11.10 Immunomedics
- 11.11 Merck
- 11.12 Millennium
- 11.13 Nordic Nanovector
- 11.14 Novartis
- 11.15 PDL BioPharma
- 11.16 Progenics Pharmaceuticals
- 11.17 Roche
- 11.18 Seattle Genetics
- 11.19 Stem CentRx
- 11.20 UCB
- 11.21 Viventia Biotechnologies

## List Of Figures

### LIST OF FIGURES

- Figure 1-1: Advantages of Antibody Drug Conjugates
- Figure 2-1: Detailed Structure of Antibody Drug Conjugate
- Figure 2-2: Components of Antibody Drug Conjugates
- Figure 2-3: Categorization of the Types of Linkers
- Figure 2-4: Conjugation Strategies Adopted for Antibody Drug Conjugate
- Figure 3-1: Difference Between First & Second Generation Antibody Drug Conjugate
- Figure 3-2: Major Challenges of the Second Generation Antibody Drug Conjugate
- Figure 4-1: Mechanism of Antibody Drug Conjugate
- Figure 4-2: Mechanism of Brentuximab Vedotin
- Figure 4-3: Mechanism of Trastuzumab Emtansine
- Figure 5-1: Global - Antibody Drug Conjugates Market (US\$ Billion), 2014-2022
- Figure 5-2: Global - Adcetris Sales (Million US\$), 2016-2022
- Figure 5-3: Global - Kadcyla Sales (Million US\$), 2016-2022
- Figure 5-4: Global - Kadcyla Sales by Region (%), 2016
- Figure 6-1: Global - Cancer Antibody Drug Conjugates Pipeline By Phase (%), 2017 till 2022
- Figure 6-2: Global - Cancer Antibody Drug Conjugates Pipeline By Phase (Number), 2017 till 2022
- Figure 6-3: Global - Cancer Antibody Drug Conjugates Pipeline By Indication (Number), 2017 till 2022
- Figure 6-4: Global - Cancer Antibody Drug Conjugates Pipeline By Mode of Action (Number), 2017 till 2022
- Figure 6-5: Global - Cancer Antibody Drug Conjugates Pipeline By Company (Number), 2017 till 2022
- Figure 6-6: Global - Cancer Antibody Drug Conjugates Pipeline By Formulation (Number), 2017 till 2022
- Figure 7-1: Antibody Drug Conjugates Market Favorable Parameters
- Figure 7-2: Major Challenges Faced by Antibody Drug Conjugate Market
- Figure 11-1: AbGenomics - Clinical Pipeline
- Figure 11-2: Celldex - Clinical Pipeline
- Figure 11-3: Merck - Clinical Pipeline
- Figure 11-4: Millennium - Clinical Pipeline
- Figure 11-5: Novartis - Clinical Pipeline
- Figure 11-6: Progenics - Clinical Pipeline
- Figure 11-7: Roche - Clinical Pipeline

Figure 11-8: Seattle Genetics - Clinical Pipeline

Figure 11-9: Viventia - Clinical Pipeline

## List Of Tables

### LIST OF TABLES

Table 4-1: FDA Approved Antibody Drug Conjugate For Cancer

Table 4-2: Some of the Antibody Drug Conjugates under Development

Table 5-1: Drugs for Treatment of HER2-Positive Breast Cancer

### COMPANIES

AbbVie, AbGenomics Corporation, Biogen Idec, Biotest, Bristol-Myers Squibb, Celldex Therapeutics Inc, Helix BioPharma, IBC Pharmaceuticals, ImmunoGen, Immunomedics, Merck, Millennium, Nordic Nanovector, Novartis, PDL BioPharma, Progenics Pharmaceuticals, Roche, Seattle Genetics, Stem CentRx, UCB, Viventia Biotechnologies



## I would like to order

Product name: Global Cancer Antibody Drug Conjugates Market & Clinical Pipeline Insight 2022

Product link: <https://marketpublishers.com/r/G77BCCBFB7EN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G77BCCBFB7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970